/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe that these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such …
$2.52
+$0.11 (+4.71%)
EOD Sep 1, 2026
The business is unprofitable at the operating level (-34.80% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 70.5% YoY. Margins deteriorated 34.3pp alongside, both lines moving the wrong way.
ROIC dropped from -1.38% to -27.70%, capital efficiency is deteriorating. Negative free cash flow of -$3M. The business is consuming cash, not generating it.
0.0x earnings. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$2M
▼ -70.5% YoY
Net Income (TTM)
$4M
▲ +491.1% YoY
Op. Margin
-160.02%
▼ -34.3pp YoY
ROIC
-39.10%
▼ -26.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$3M
▲ +34.8% YoY
Op. Cash Flow (TTM)
-$3M
▲ +34.7% YoY
Net Debt
-$3M
Net Cash Position
Cash & Equiv.
$3M
5Y CAGR: -0.1%
Continue Research
SourceComputed from the 10-Q filed 13 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 14 Aug 2026. How this is calculated.
Price from market data, last close as of 1 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
At a P/E of 0.0, HeartCore Enterprises (HTCR)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, HeartCore Enterprises scores 20/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 92.9%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
HeartCore Enterprises scores 20 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -160.0% operating margin and a -39.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, HeartCore Enterprises pays a regular dividend of about $2.34 per share per year (typically in quarterly installments), a yield of roughly 92.9% at the current price. That is a payout ratio of about 83.1% of earnings, so the dividend is covered, with less cushion. HeartCore Enterprises has grown the dividend at roughly 296.0% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For HTCR's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. you should weigh HTCR's valuation and scores 20/100 on quality (lower-quality). It also yields about 92.9%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.